pp-251 Solution for infusion
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Neoplasm, Cancer, Pancreas tumor, Small-cell lung cancer, Ovary tumor, Gastrointestinal disease
Clinical stage: Phase 2
Modality: Small molecule inhibitor
Mechanism & Target: Anticancer permeability enhancer, Anticancer antimetabolite, Cell cycle inhibitor, Anticancer chemosensitizer
Route & form: Oral
Differentiation: medicine is a differentiated SN-38 formulation designed to enhance tumor-selective exposure and systemic pharmacologic activity in solid tumors, particularly small cell lung cancer (SCLC)."
Manufacturer #39669
Clinical-stage company developing IgG-cleaving enzyme therapies for transplant and autoimmune disease. Lead program targets antibody-mediated rejection desensitization prior to kidney transplant. Advances Phase 3 pivotal programs with global regulatory development partnerships.
None